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Identiﬁcation of new players in iron metabolism, such as hepcidin, which regulates
ferroportin and divalent metal transporter 1 expression, has improved our knowledge of
iron metabolism and iron-related diseases. However, from both experimental data and
clinical ﬁndings, “iron-related proteins” appear to also be involved in the metabolism of
other metals, especially divalent cations. Reports have demonstrated that some metals
may affect, directly or indirectly, the expression of proteins involved in iron metabolism.
Throughout their lives, individuals are exposed to various metals during personal and/or
occupational activities. Therefore, better knowledge of the connections between iron
and other metals could improve our understanding of iron-related diseases, especially
the variability in phenotypic expression, as well as a variety of diseases in which iron
metabolism is secondarily affected. Controlling the metabolism of other metals could
represent a promising innovative therapeutic approach.
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INTRODUCTION
Iron is ametal found at very high levels inEarth’s crust that is essen-
tial for cell life due to its major role in most biological systems and
metabolic pathways through its involvement in oxygen transport
and delivery, and participation in a large number of enzymatic
processes (Crichton, 2001a). In addition, iron may participate in
the genesis of reactive oxygen species (ROS) through the Fenton
and Haber–Weiss reactions (Wardman and Candeias, 1996). Pro-
duction of ROS alters proteins, lipids, and DNA during oxidative
stress favoring the development of cellular alterations that lead to
the development of lesions in organs (Meneghini, 1997; Crichton,
2001b).
During the beginning of the third millenary, knowledge
of iron metabolism has consistently progressed with the iden-
tiﬁcation of numerous genes encoding iron metabolism pro-
teins, including hepcidin, and a better understanding has been
gained of systemic iron metabolism. These discoveries led to
the identiﬁcation of a strong potential relationship between iron
and other metals, contributing to an understanding of previ-
ous unexplained ﬁndings described primarily during the 20th
century.
Here, our objective is to provide evidence of true metal
interactions that likely represent a way of better under-
standing metal metabolism and metal-related diseases in the
future.
IRON METABOLISM PLAYERS
Iron is a transition metal with a metabolism characterized by the
following: (i) a major role of iron found in plasma (1–2 mg),
which is delivered to every cell in the body; (ii) constant recycling
of iron associated with hemoglobin within erythrocytes, followed
by iron export toward plasma (20 mg/day); (iii) the absence of an
active, iron excretory process, and iron losses (1–2 mg/day) are
uncontrolled; and (iv) a tuning of digestive absorption that must
strictly compensate for iron losses (Andrews, 1999, p. 677). Thus,
most of the iron required by the organism daily (20 mg/day) is
provided by the erythrophagocytosis process that occurs within
macrophages.
In plasma (Andrews, 1999), iron is linked in its ferric form
to transferrin, a β-globin protein of hepatocytic origin. The iron
saturation of transferrin is 30–45%. Iron-transferrin is taken up
by cells through transferrin receptor 1 via an endocytic process.
An additional step occurs in the endocytic vesicle and involves
divalent metal protein 1 (DMT1; Fleming et al., 1997, 1998; Gun-
shin et al., 1997), which is encoded by the SLC22a1 gene. After
reduction of ferric iron by the STEAP 3 protein (Lambe et al.,
2009), the iron is transferred to the cytosol, where it becomes
available for cells. Plasma iron is directed mainly to erythrob-
lasts, where it associates with heme for hemoglobin synthesis
(Andrews, 1999, p. 677). In some cases, mainly during iron-
overload diseases, non-transferrin-bound iron may appear in
the plasma (Hershko and Peto, 1987; Brissot et al., 2012). Non-
transferrin-bound iron associates mainly with low-molecular-
weight molecules. This form of iron can be avidly taken up by
parenchymal cells, especially hepatocytes (Brissot et al., 1985).
Proteins expressed at the hepatocyte membrane level, such as
ZIP14 (Liuzzi et al., 2006), could participate in this process,
conferring to hepatocytes, and more globally the liver, a major
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role in the control of excess iron in the plasma by offering an
iron-storage site.
Macrophages ensure recycling of senescent erythrocytes
(Andrews, 1999). The last phase of this process involves the fer-
roportin protein (SLC40a1 gene), which transfers ferrous iron
toward the plasma (Donovan et al., 2000; McKie et al., 2000). Next,
iron is oxidized by the ceruloplasmin protein, a multicopper oxi-
dase secreted by the liver (Osaki et al., 1966; Miyajima et al., 1987;
Harris, 1995). Iron is subsequently taken in charge by transferrin
(Andrews, 1999).
Iron losses are mostly related to cutaneous and digestive cell
peeling, urine leakage, and regular (menstruations) or occasional
bleeding.
Digestive iron absorption occurs mostly in the duodenum and
involves enterocytes (Andrews, 1999). Non-heme ferric iron is
taken up from the digestive lumen by DMT1 (Fleming et al., 1997,
1998; Gunshin et al., 1997) after an oxidation process that could
involve Dcytb, a ferrireductase protein (McKie et al., 2001). Heme
iron could be taken up from nutrients by a speciﬁc transporter.
Heme carrier protein 1 is a candidate (Shayeghi et al., 2005),
allowing further heme processing by heme-oxygenase 1 within
enterocytes, and then iron reaches the cytoplasmic iron pool
(Fleming et al., 1997, 1998; Gunshin et al., 1997). In both cases,
the transfer of iron in the plasma as ferrous iron is ensured by the
ferroportin protein (Donovan et al., 2000; McKie et al., 2000). Iron
is then oxidized in ferric iron by hephaestin, another multicopper
oxidase anchored in the cell membrane at the basolateral level
(Vulpe et al., 1999; Anderson et al., 2002), and/or ceruloplasmin,
allowing iron to interact with plasma transferrin and its delivery
to other cells (Andrews, 1999).
SYSTEMIC REGULATORS OF IRON METABOLISM
Regulation of systemic iron metabolism involves hepcidin, a
cysteine-rich, 25 amino acid, iron-inducible peptide secreted by
the liver (Nicolas et al., 2001; Park et al., 2001; Pigeon et al.,
2001). Schematically, serum hepcidin may interact with ferro-
portin protein localized on the cellmembrane of macrophages and
enterocytes, inducing its internalization and degradation (Nemeth
et al., 2004). The global effect is a control of iron egress from cells,
avoiding increased transferrin saturation, which would expose to
the appearance of non-transferrin-bound iron and to the devel-
opment of parenchymal iron overload, as observed during genetic
hemochromatosis (Loréal et al., 2005).
Iron is then sequestered in macrophages or enterocytes within
ferritin, the iron-storage protein (Munro and Linder, 1978; Theil,
1987). In macrophages, iron is mobilized toward the plasma as
required based on the plasma hepcidin level. Thus, iron can be
available immediately after a decrease in hepcidin. In enterocytes,
stored iron (corresponding to the classical “mucosal block”) is lost
during cell peeling. This mechanism is related to the low ratio
between iron originating every day from enterocytes compared to
macrophages and likely occurs to control iron storage over a longer
period (Andrews, 1999).
Hepcidin regulators play a critical role in the maintenance
of adequate serum hepcidin levels and, therefore, in the con-
trol of serum iron and systemic iron homeostasis (Muckenthaler,
2008). Inducers of hepcidin expression by hepatocytes include
excess iron (Pigeon et al., 2001) and inﬂammation (Nemeth
et al., 2003). Increased hepcidin gene transcription related
to iron involves the hemojuvelin/bone morphogenetic/SMAD
(HJV/BMP/SMAD) pathway, which is activated following BMP6
over-expression (Andriopoulos et al., 2009; Meynard et al., 2009).
In addition, HFE and TFR2 proteins, which are both expressed
on the hepatocyte cell membrane, participate in the induc-
tion of hepcidin expression under conditions of excess iron.
Although a role of increased serum transferrin saturation has
been proposed (Goswami and Andrews, 2006; Muckenthaler,
2008), the molecular mechanism involved and the interaction
with the HJV/BMP/SMAD pathway are not fully understood.
Such regulation contributes to limiting iron excess. The con-
trol of hepcidin levels is deﬁcient during genetic hemochro-
matosis related to HFE, TFR2, HJV, or HAMP mutation in
humans, leading to iron-overload diseases (Brissot et al., 2011).
Inﬂammation strongly increases hepcidin expression through the
IL6/STAT3 pathway (Wrighting and Andrews, 2006; Pietrangelo
et al., 2007; Verga Falzacappa et al., 2007), contributing to lim-
ited iron bioavailability for either growing pathogenic agents
during infectious disease or oxidative stress during chronic
inﬂammation.
Factors reducing hepcidin expression include hypoxia. Such
impact of hypoxia increases serum iron and transferrin satu-
ration, allowing intense erythropoiesis to compensate for tissue
hypoxia (Muckenthaler, 2008). Whether the impact of hypoxia on
HAMP transcription involves a stimulation of hypoxia inducible
factor (HIF; Peyssonnaux et al., 2007) remains to be deﬁnitively
determined. Recent arguments suggest that factors secreted dur-
ing erythropoiesis could impact hepatocytes and limit hepcidin
expression (Muckenthaler, 2008; Zhao et al., 2013).
Taken together, these ﬁndings put the focus on the hepcidin
and ferroportin duo.
REGULATION OF INTRACELLULAR IRON METABOLISM
Within cells, an integrated system ensures the control of total
iron content and distribution. The iron responsive element (IRE)
and iron regulatory protein (IRP) together control the expres-
sion of proteins encoded by mRNA exhibiting an IRE nucleotide
motif localized in the 5′UTR or 3′UTR (Hentze et al., 1987, 1988).
When IRPs are active, they interact with the IRE, limiting the
expression of proteins, such as ferritin, which has an IRE in
its 5′UTR, and stabilizing mRNA, such as transferrin receptor
1 mRNA, which displays IRE motifs in its 3′UTR. This interac-
tion is promoted by intracellular iron deﬁciency, the global effect
being the promotion of iron ingress into the cell and associating
with proteins that require this metal to reach their full activities.
Conversely, in the presence of iron excess, the decrease in IRP
activities leads to increased ferritin protein expression, favoring
the storage of iron in a chemically inactive form, and decreased
cellular iron entry due to a strong decrease in transferrin receptor
1 mRNA expression. Together, these processes avoid the produc-
tion of ROS by limiting the amount of iron available for their
production.
There are other iron-related proteins coded by mRNAs con-
taining an IRE in their 5′UTR or 3′UTR, including DMT1 and
ferroportin (Gunshin et al., 1997; McKie et al., 2000).
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IRON-RELATED DISEASES CAN BE ASSOCIATED WITH
ALTERATIONS IN THE METABOLISM OF OTHER METALS
Iron homeostasis is lost during iron-related diseases. Schemati-
cally, three conditions can be found: (i) true iron deﬁciency related
to insufﬁcient intake, malabsorption, or excessive losses (Miller,
2013); (ii) iron misdistribution linked to systemic inﬂammation
or cell-speciﬁc processes (Ganz and Nemeth, 2009); and (iii) sys-
temic iron excess associated with genetic iron overload (Brissot
et al., 2011) or anemia related to hematological cause (Gardenghi
et al., 2010), with or without transfusions. Clinical, biological, and
genetic characterization of these conditions pinpoints the links
between iron and other metals.
IRON DEFICIENCY
Iron deﬁciency has been associated with abnormal absorption of
metals from the digestive lumen. Pollack et al. (1965) reported a
signiﬁcant impact of iron deﬁciency, which was different accord-
ing to etiology. In the rat, anemia consecutive to bleeding induced
the absorption of manganese, cobalt, and iron. During iron deﬁ-
ciency related to poor iron intake, zinc absorption was increased
(Pollack et al., 1965). Notably, a biological marker of chronic
iron deﬁciency is an increase in zinc-protoporphyrin, which
reﬂects the substitution of iron by zinc as a substrate for fer-
rochelatase during the last step of heme synthesis (Labbe et al.,
1999). Conversely, absorption of calcium, magnesium, mer-
cury, and copper was not signiﬁcantly affected. Interestingly,
supplementation of the diet with iron did not modify cobalt
and manganese hyperabsorption. More recently, it was reported
(Nam and Knutson, 2012) that iron status, especially iron deﬁ-
ciency, may increase the expression of ZIP 5, a zinc transporter,
and conversely decreases the hepatic expression of ZIPs 6, 7,
and 10. Moreover, iron-deﬁcient rats had higher hepatic cop-
per concentrations. The authors underlined that zinc transporters
could play a role in hepatic iron/metal homeostasis during iron
deﬁciency.
In particular, the relationship between iron deﬁciency and
non-iron metals has been investigated in the brain. Iron deﬁ-
ciency may increase zinc concentration in the midbrain and
hippocampus, whereas copper concentrations have been reported
to be increased in the cerebral cortex and corpus striatus (Shukla
et al., 1989). In addition, Erickson (Erikson et al., 2004) showed
that iron deﬁciency induced an increase in manganese concen-
tration in the putamen, globus pallidus, and substantia nigra.
Zinc concentrations were also increased. The authors suggested
that an increase in DMT1 expression related to iron deﬁciency
could be involved. In the same way, iron depletion and load-
ing increased brain manganese concentrations in young rats;
this impact remained signiﬁcant for 9 weeks. Moreover, the
uptake of manganese by the brain, liver, kidneys, and bones
was signiﬁcantly increased by excess iron in younger rats. Man-
ganese supplementation increased radioactive iron uptake by
the brain, liver, and kidneys of rats receiving control and Fe-
deﬁcient diets compared to rats supplemented with dietary iron
(Chua and Morgan, 1996). DMT1 could be involved. Indeed,
in Belgrade rats, the DMT1 mutation similarly affected man-
ganese and iron metabolism, suggesting that they share similar
transport mechanisms in the cells of erythroid tissue, duodenal
mucosa, kidneys, and the blood–brain barrier (Chua and Morgan,
1997).
Another argument for an impact of iron deﬁciency on the
metabolismof othermetals is that iron deﬁciency confers a suscep-
tibility to tissue accumulation of heavy, potentially toxic, metals,
such as cadmium, nickel, and lead (Six and Goyer, 1972; Flana-
gan et al., 1978; Tandon et al., 1993). Mechanisms may include
increased digestive absorption and metal accumulation in tissues,
such as has been reported for cadmium (Flanagan et al., 1978). For
nickel, a dynamic study in rats argued for increased absorption and
decreased excretion (Tallkvist and Tjalve, 1997).
IRON MISDISTRIBUTION
The most frequent cause of iron misdistribution is the inﬂamma-
tory process, which is the secondmost common etiology of anemia
worldwide through the anemia of chronic disease (ACD; Weiss
and Goodnough, 2005). Regarding iron metabolism,ACD is char-
acterized by macrophagic iron sequestration and decreased iron
absorption. The underlying mechanism involves increased plasma
hepcidin levels, which limit the expression of ferroportin on the
cell membrane (Ganz, 2011). Such situations have been associated
with alterations in the metabolism of other metals. Thus, zinc
and copper serum concentrations were reported to be increased in
an acute model of inﬂammation (Milanino et al., 1986). Notably,
zinc plays a major role in inﬂammation and the immune response,
and zinc supplementation may improve innate immunity during
inﬂammatory/infectious processes in acute, septic models (Knoell
et al., 2009; Bao et al., 2010). Recently, zinc deﬁciency was reported
to up-regulate the JAK/STAT3 pathway and could contribute to the
severity of inﬂammation (Liu et al., 2014). The concentrations of
calcium, strontium, and iron are increased in neutrophil granules,
but the manganese increase in leukocytes was not localized to the
granules (Hallgren et al., 1989). Whether the impact of inﬂamma-
tion on non-iron metals is related to decreased iron bioavailability
and/or due to other independent mechanisms, including cytokine
production, is not known.
Regarding heavy metals, a recent report described a role for
ZIP14, which is involved in the cellular uptake of non-transferrin-
bound iron and cadmium accumulation during inﬂammation
(Min et al., 2013).
SYSTEMIC IRON OVERLOAD
Systemic iron-overload diseases include genetic iron overload –
involving mutations in iron-related genes –, and secondary iron
overload associated with hematologic diseases, and iron excess
associated with liver diseases.
Regarding genetic iron-overload diseases, reports empha-
size disturbances in other metals. Thus, during HFE-related
hemochromatosis, in which low hepcidin levels lead to an abnor-
mal increase in both digestive iron absorption and macrophagic
iron release, an increase in hepatic zinc concentration has been
reported (Adams et al., 1991), whereas plasma zinc concentration
was normal (Brissot et al., 1978).
Abnormalities in manganese metabolism have been reported,
in addition to those reported by Chua and Morgan (1997).
In a mouse model of genetic hemochromatosis, Jouihan et al.
(2008) showed that mitochondrial manganese uptake was altered,
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leading to mitochondrial dysfunction. Moreover, Kim et al. (2013)
reported that the digestive absorption of manganese was strongly
increased in Hfe−/− mouse model further emphasizing the
relationship between iron and manganese metabolism.
A metal for which strong interactions with iron have been
reported is cobalt. Cobalt may mimic iron deﬁciency by stabilizing
HIF and, in turn, induce a large number of genes related to hypoxia
and iron metabolism (Schuster et al., 1989; Yuan et al., 2003;
Karovic et al., 2007). Cobalt may also reduce hepcidin expres-
sion by hepatocytes without involvement of the transcriptional
factor HIF-1 (Braliou et al., 2008). Digestive absorption of cobalt
was increased in hemochromatotic patients or patients exhibiting
liver cirrhosis complicated by iron overload (Valberg et al., 1969;
Olatunbosun et al., 1970). In patients with hepatic steatosis or cir-
rhosis and normal iron status, digestive absorption of cobalt and
iron was not affected compared to controls. Conversely, in patients
with cirrhosis and iron deﬁciency, both cobalt and iron absorption
were increased to similar levels as a group of patients exhibiting
iron deﬁciency alone.
Blood lead concentration was found to be increased during
genetic hemochromatosis, in contrast with transfusional iron
overload (Barton et al., 1994). Iron depletive treatment performed
by phlebotomies in genetic hemochromatotic patients induced an
increase in cadmium uptake (Akesson et al., 2000).
ALTERATIONS OF NON-IRON METALS MAY IMPACT IRON
METABOLISM
Numerous reports have studied the impact of modulations of non-
iron metals on iron metabolism. Here, we will focus on copper,
zinc, cobalt, manganese, and lead.
COPPER
Alterations in copper metabolism may strongly affect iron
metabolism. Thus, the discovery of mutations in the ceruloplas-
min gene provided an explanation for the peculiar phenotype
of systemic iron overload involving the brain, which contrasts
low plasma iron levels and concomitant anemia (Miyajima et al.,
1996; Gitlin, 1998; Loréal et al., 2002). No signiﬁcant alterations
in copper metabolism were found. These effects are related to the
role of ceruloplasmin, a multicopper oxidase, in oxidizing fer-
rous iron before its transferrin linkage in plasma. This role of
ferroxidase activity has been reported for many years (Osaki et al.,
1966). Notably, copper metabolism is a therapeutic target during
Wilson disease, which is characterized by a toxic accumulation
of copper due to a defect in the ATP7B gene (Tanzi et al., 1993;
Huster, 2010). Thus, zinc oral supplementation has been used to
limit copper absorption. The mechanisms involved are competi-
tion between zinc and copper, as well as an induction of enterocyte
metallothioneins by zinc, as they can link copper as well as zinc
(Schilsky et al., 1989). However, whether zinc is associated with
copper chelating therapy during the active or maintenance phase
of treatment remains to be discussed (Schilsky, 2009). Recently,
the impact of zinc on copper metabolism was reinforced by the
description of a new form of systemic iron overload (Videt-Gibou
et al., 2009) related to secondary aceruloplasminemia resulting
from excessive zinc intake (Nations et al., 2008). The defect is
corrected by copper supplementation.
ZINC
Modulations in zinc metabolism may also affect iron metabolism.
Thus, in swine, zinc supplementation induces liver iron deple-
tion without modulation of hepatic copper content (Cox and
Hale, 1962). In rats, zinc supplementation decreased growth and
favored anemia (Cox and Harris, 1960). O’Neil-Cutting et al.
(1981) demonstrated that, in rats receiving low amounts of cop-
per, a zinc-enriched diet induced anemia and low hepatic copper
concentrations. This effect was not observed in animals with a
balanced zinc diet, supporting the potential impact of zinc on
erythropoiesis when appropriate cofactors exist. Another study
suggested that zinc supplementation during gestation and lacta-
tion could have a differential effect on liver iron content, whereas
copper content is not affected (Ketcheson et al., 1969). Taken
together, these reports support that the potential effects of zinc
on other metals should be evaluated, despite the presence of stud-
ies supporting recommendations for zinc supplementation (Hess
and King, 2009). Moreover, despite numerous publications on
the impact of zinc on the brain, especially during neurodegener-
ative diseases in which abnormal excess levels of iron have been
reported, the effect of zinc appears to be ambiguous (review in
Kawahara et al., 2014). Zinc has been proposed as an antioxidant
molecule to improve neurodegenerative disease. However, zinc
has also been suspected to favor Alzheimer’s disease and neuronal
death. Knowing the potential impact of zinc on iron metabolism,
and whether this effect in neurodegenerative disorders is partly
related to abnormal ironmetabolism in the brain,warrants further
investigation.
COBALT
In trace amounts, cobalt is essential, as it is an integral part of
the vitamin B12 complex and has a physiological impact on iron
metabolism by contributing to erythropoiesis (Simonsen et al.,
2012). In addition, cobalt supplementation may facilitate toler-
ance to hypobaric hypoxia (Shrivastava et al., 2008), which could
be related to the modulation of HIF-regulated genes in order to
promote oxygenation. Cobalt chloride supplementation has been
evoked as a potential doping strategy in athletes (Lippi et al., 2005).
To date, cobalt is not explicitly prohibited by world anti-doping
agencies, despite its potential toxicity in the case of abnormal
exposure. An increase in hemoglobin/hematocrit levels and poly-
cythemia has been recorded in humans, rats, and dogs exposed
to cobalt, demonstrating a strong impact on iron metabolism
(see the US Agency for Toxic Substances and Disease Registry:
http://www.atsdr.cdc.gov/toxproﬁles/tp33.pdf).
MANGANESE
Manganese, an essential component of metalloenzymes, is also
essential for cell life. One of the main manganese-requiring
enzymes is manganese superoxide dismutase, which plays a major
role in counteracting oxidative stress, especially with iron, by
detoxifying the superoxide radicals (Martinez-Finley et al., 2013).
Some published data support an impact of manganese on iron
metabolism. In cattle, oralmanganese supplementation in animals
receiving a low copper diet leads to decreased DMT1 expression
in enterocytes. In addition, the down-regulation of hepcidin and
ferroportin mRNA was found in the liver of animals receiving a
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copper-deﬁcient diet alone (Hansen et al., 2010). In rats, during
the neonatal period in animals receiving an iron-deﬁcient diet,
manganese supplementation of dams was reported to increase
brain levels of manganese, chromium, zinc, cobalt, aluminum,
molybdenium, and vanadium in the pups. In addition, iron
decreased and copper increased in the brain (Garcia et al., 2007).
LEAD
For many years, lead exposure was reported to strongly modu-
late iron metabolism. Multiple mechanisms are likely involved in
this interaction. As known for a long time, excess lead inhibits
δ-aminolevulinic acid dehydratase and ferrochelatase activities,
in particular, induces zinc protoporphyrin accumulation in ery-
throcytes, and favors the occurrence of microcytic hypochromic
anemia (Ku et al., 1990; Braun, 1999). In addition, lead has been
reported to limit the transfer of iron from endosomes toward
the cytoplasm (Qian et al., 1997). More recently, lead expo-
sure in rats was reported to decrease serum iron and transferrin
saturation levels (Moshtaghie et al., 2013). In workers exposed
to lead, copper, and ceruloplasmin serum concentrations are
increased, but no signiﬁcant alteration in iron and zinc serum
levels has been found (Kasperczyk et al., 2012). Potential inter-
actions between lead and ceruloplasmin protein may explain a
decrease in ceruloplasmin-linked ferroxidase activity (Leelaku-
nakorn et al., 2005). In vitro, lead decreased transferrin synthesis in
a human hepatic cell line (Barnum-Huckins et al., 1997). However,
such an impact has not been reported in lead-exposed workers
(Kasperczyk et al., 2012).
MOLECULAR EVENTS AND PATHWAYS LINKING IRON
METABOLISM TO NON-IRON METAL METABOLISM
A ROLE FOR PROTEINS INVOLVED IN IRON TRANSPORT
There are proteins playing a role in the processes contributing to
maintain iron homeostasis that have been associated to non-iron
metal metabolisms (Figure 1).
DMT1 is a potential major link between iron and other divalent
cations. The ﬁrst description of DMT1 was associated with iron
metabolism, especially in enterocytes and erythroblasts (Gunshin
et al., 1997). However, DMT1 was also demonstrated to be able to
take in charge other metals (Gunshin et al., 1997). Such a poten-
tial role of DMT1 with metals other than iron was reinforced by
recent data showing that the efﬁcacy of metal transport was very
important for Cd2, Fe2+, Co2+, and Mn2+, and lesser for Zn2+,
Ni2+, and Vo2+. However, the authors found that DMT1 expres-
sion did not stimulate the transport of Cr2+, Cr3+, Cu+, Cu2+,
Fe3+, Ga3+, Hg2+, or VO+ (Illing et al., 2012). In addition, iron
processing by DMT1 was competitively inhibited by Co2+ and
Mn2+.
Ferroportin is also a candidate for interactions between iron
and other metals. Ferroportin was initially reported as the iron
exporter. However, recent data suggest that manganese, zinc, and
cobalt could also be taken in charge by ferroportin (Troadec et al.,
2010; Yin et al., 2010). This ﬁndingwas conﬁrmed by data showing
that ferroportin expression in Xenopus oocytes enhance the efﬂux
of 65Zn and 57Co but not 64Cu, 109Cd, or 54Mn. In addition,
iron, zinc, and cobalt egress were inhibited by oocyte exposure to
hepcidin (Mitchell et al., 2014).
Transferrin is the major plasma protein involved in iron deliv-
ery to cells. However, some data suggest that cobalt competes
with iron on transferrin (Harrington, 1992). Thus, biochemical
determination of non-transferrin-bound iron levels can be altered
in the presence of cobalt (Gosriwatana et al., 1999). Others have
suggested that transferrin may interact with manganese (Aschner
and Gannon, 1994), indium, bismuth (Li et al., 1996; Zhang et al.,
2004), copper (O’Neil-Cutting et al., 1981), and chromium (Har-
ris, 1977). Transferrin has also been reported to interact with lead
when present in excess (Leelakunakorn et al., 2005). In addition,
when saturated by non-iron metals, transferrin could compete
with iron-transferrin during its interaction with transferrin recep-
tor 1 (Ha-Duong et al., 2008; El Hage Chahine et al., 2012). Taken
together, these data suggest that metals other than iron could, by
using transferrin as a Trojan horse, play a role inmetal distribution
within the body. This could also theoretically modulate the kinet-
ics of iron ingress into cells. However, the impact on iron uptake
is likely moderate due to the ratios of concentrations of different
metals and iron in plasma and to a lower afﬁnity of these non-iron
metals for transferrin receptor 1 (El Hage Chahine et al., 2012).
The low amount of non-iron metal linked to transferrin has been
recently conﬁrmed in mouse serum (Herrera et al., 2014). The
same authors studying wild-type mice and transferrin-deﬁcient
mice also showed that transferrin does not play a major role in the
delivery of manganese, copper, or zinc to tissues. Moreover, they
suggest that an increase of tissue manganese found in transferrin
deﬁcient mice is linked to an indirect effect of transferrin deﬁ-
ciency on hepcidin expression or iron metabolism (Herrera et al.,
2014). The interaction of transferrin with In3+ andCu2+ has been
shown to induce conformational changes similar to Fe3+; in addi-
tion, Al3+ causes a conformational change of a somewhat smaller
magnitude, whereas Hf4+ (hafnium) does not induce signiﬁcant
conformational changes (Grossmann et al., 1993). Gallium trans-
ferrin is also taken in charge by the transferrin receptor (Chikh
et al., 2007).
Taken together, these ﬁndings suggest that physiological or
pathological modulation of the expression or activity of iron pro-
teins, such as DMT1 or ferroportin, as well as transferrin, could
modify the metabolism of other metals.
A ROLE FOR HEPCIDIN IN THE METABOLIC CONTROL OF NON-IRON
METALS
Hepcidin, the key regulator of iron bioavailability in plasma, exerts
its role by controlling the expression of ferroportin protein, its
main target, on the cell membrane (Figure 1).
Hepcidin may also modulate DMT1 expression. DMT1 expres-
sion and activity were decreased in vitro at the apex of Caco-2
cells after exposure of the basolateral part of the cells to hepcidin
(Brasse-Lagnel et al., 2011). Notably, during genetic hemochro-
matosis, DMT1 and ferroportin are highly expressed in entero-
cytes, as observed during iron deﬁciency, and the inverse correla-
tion between serum iron parameters and protein expression found
in enterocytes of iron-deﬁcient patients disappeared in genetic
hemochromatosis patients (Zoller et al., 2001). Whether hepcidin
plays a role on the modulation of DMT1 in addition to its impact
on ferroportin has not been addressed. Molecular mechanisms
could involve the proteasome (Brasse-Lagnel et al., 2011).
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FIGURE 1 | Schematic representation of potential connections between
iron, hepcidin and non-iron metals. Special focus has been made on three
major processes in iron metabolism – digestive iron absorption, iron
mobilization and cell iron delivery (yellow boxes) – and some major proteins
and parameters directly involved in iron metabolism (blue boxes). White
boxes indicate non-iron metals for which relationships have been reported
with adjacent iron metabolism protein (For details see in the text). Red arrows
represent an involvement of the protein in the targeted biological process.
Blue arrows indicate an impact of the protein on the expression/activity of the
targeted protein.
These ﬁndings suggest that physiological and pathological
modulation of hepcidin levels in plasma could also strongly mod-
ulate metal ﬂuxes in the body. Low levels of hepcidin, as observed
during iron deﬁciency, genetic hemochromatosis, or liver diseases,
favor the uptake of iron and, likely, non-iron metals that can be
processed by DMT1 and/or ferroportin. Such mechanisms could
contribute to the clinical ﬁndings reported in older (aforemen-
tioned) studies, especially those regarding cobalt (Valberg et al.,
1969; Olatunbosun et al., 1970).
In addition, hepcidin expression could be regulated by non-
iron metals at the transcriptional level. Cadmium, copper, and
zinc could modulate hepcidin expression through interactions
between themetal-responsive element located in the hepcidin pro-
moter with metal transcription factor 1 (MTF1; Balesaria et al.,
2010). In addition, the authors showed that hepcidin expression
was increased by cadmium, copper, and zinc salts in HuH7 hep-
atoma cells and decreased by cobalt and iron salts. In addition,
methallothionein-1 expression followed hepcidin modulation by
non-iron metals, but not by iron per se.
Animals developing hemochromatosis related to the Hfe−/−
genotype in association with abnormally low hepcidin levels were
recently reported to exhibit signiﬁcant modulation of their diges-
tive microbiota. Whether this observation is related to iron excess
only or whether it involves a molecular defect consecutive to HFE
dysfunction is not known. However, as bacteria present with dif-
ferential equipment, including siderophores, for acquiring metals
from the diet and different requirements regarding other metals,
modulation of microbiota during iron overload could have an
impact on the absorption of iron or other metals.
Finally, hepcidin has been reported to physically interact in
plasma with transition metals, including copper, nickel, and zinc
(Tselepis et al., 2010). Whether this observation has signiﬁcant
biological relevance is not currently known.
INTERACTIONS BETWEEN IRON AND HEPCIDIN AND THE
METAL CONNECTION IN IRON-RELATED DISEASES
Until now, one of the major problems in iron-related diseases
has been understanding the variability of clinical and biological
expression.
This is especially true in genetic hemochromatosis related to
the p.Cys282Tyr mutation. The homozygous mutation is found in
three subjects per thousand in the Caucasian population. How-
ever, an increase in serum transferrin saturation, which is the
earliest biochemical expression of the disease, only occurs in 50%
of homozygous subjects. The clinical manifestations that impact
life expectancy orwelfare are even rarer (Brissot et al., 2011). These
discrepancies led to a search for putative genetic cofactors associ-
atedwith the p.Cys282Tyrmutation. Some explanations have been
proposed, including digenism or polymorphisms in other genes
directly or indirectly involved in iron metabolism (Merryweather-
Clarke et al., 2003; Island et al., 2009). In addition, an impact of
hormonal status (Latour et al., 2014) and environmental factors
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related to metabolic syndrome (Desgrippes et al., 2013) has been
found.
The identiﬁcation of interconnections between non-iron met-
als and their potential impact on iron metabolism provides a new
way to explore the differential expression of iron-related diseases,
especially in a world where every individual may be exposed to
various metals during personal and occupational life, as well as
after prosthesis implantation.
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